Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia

Clinical Chemistry

Volumn 53, Issue 3, 2007, Pages 399-404

  Purwosunu, Yuditiya ^a,b   Sekizawa, Akihiko ^a   Koide, Keiko ^a   Farina, Antonio ^a,c   Wibowo, Noroyono ^b   Wiknjosastro, Gulardi Hanifa ^b   Okazaki, Shiho ^a   Chiba, Hiroshi ^a   Okai, Takashi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LIVER ENZYME; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HEMOLYSIS; HUMAN; LABOR ONSET; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANT WOMAN; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA EXTRACTION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; FEMALE; HUMANS; MIDDLE AGED; PLASMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRE-ECLAMPSIA; PREGNANCY; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33947423914     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.081372     Document Type: Article

References (32)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785-99.
2. Redman CW, Sargent IL Latest advances in understanding preeclampsia. Science 2005;308:1592-4.
3. Feng Q, Liu K, Liu YX, Byrne S, Ockleford CD. Plasminogen activators and inhibitors are transcribed during early macaque implantation. Placenta 2001;22:186-99.
4. Hu ZY, Liu YX, Liu K, Byrne S, Ny T, Feng Q, Ockleford CD. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 194(Pt 2):183-95, 1999.
5. Poon LL, Leung TN, Lau TK, Lo YM. Presence of fetal RNA in maternal plasma. Clin Chem 2000;46:1832-4.
6. Ng EK, Leung TN, Tsui NB, Lau TK, Panesar NS, Chiu RW, et al. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem 2003;49:727-31.
7. Farina A, Rizzo N, Concu M, Banzola I, Sekizawa A, Grotti S, et al. Lower maternal PLAC1 mRNA in pregnancies complicated with vaginal bleeding (threatened abortion <20 weeks) and a surviving fetus. Clin Chem 2005;51:224-7.
8. Tjoa ML, Jani J, Lewi L, Peter I, Wataganara T, Johnson KL, et al. Circulating cell-free fetal messenger RNA levels after fetoscopic interventions of complicated pregnancies. Am J Obstet Gynecol 2006;195:230-5.
9. Farina A, Chan CW, Chiu RW, Tsui NB, Carinci P, Concu M, et al. Circulating corticotropin-releasing hormone mRNA in maternal plasma: relationship with gestational age and severity of preeclampsia. Clin Chem 2004;50:1851-4.
10. Martin JN, Blake PG, Perry KG, McCaul JF, Hess LW, Martin RW. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164: 1500-9; discussion 1509-13.
11. Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemost 1984;52:124-6.
12. de Boer K, Lecander I, ten Cate JW, Borm JJ, Treffers PE. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988;158:518-22.
13. Estelles A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intra-uterine fetal growth retardation. Blood 1994;84:143-50.
14. Estelles A, Gilabert J, Grancha S, Yamamoto K, Thinnes T, Espana F, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 1998;79:500-8.
15. Gilabert J, Estelles A, Grancha S, Espana F, Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Hum Reprod 1995;10(Suppl 2): 121-31.
16. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994;101:488-92.
17. Estelles A, Grancha S, Gilabert J, Thinnes T, Chirivella M, Espana F, et al. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol 1996;149:1229-39.
18. Nakashima A, Kobayashi T, Terao T. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest 1996;42:95-101.
19. Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A, Peters WH, et al. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am J Obstet Gynecol 2002;187:1019-25.
20. van Wersch JW, Ubachs JM. Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 1991;29: 45-50.
21. DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wail. Am J Pathol 1999;155:293-301.
22. Hasselmann DO, Rappl G, Tilgen W, Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001;47:1488-9.
23. Feinberg RF, Kao LC, Haimowitz JE, Queenan JT, Wun TC, Strauss JF, et al. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 1989;61:20-6.
24. Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989;74:1332-8.
25. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, Knofler M. Tumor necrosis factor-α inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. J Clin Endocrinol Metab 2004;89:812-22.
26. Bonnar J, Daly L, Sheppard BL. Changes in the fibrinolytic system during pregnancy. Semin Thromb Hemost 1990;16:221-9.
27. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218-24.
28. Lau TW, Leung TN, Chan LY, Lau TK, Chan KC, Tam WH, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem 2002;48:2141-6.
29. Thogersen AM, Jansson JH, Wester PO. Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction. Int J Cardiol 1996;56:53-9.
30. Yin KH, Koh SC, Malcus P, SvenMontan S, Biswas A, Arulkumaran S, et al. Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy. J Obstet Gynaecol Res 1998;24:231-8.
31. Belo L, Santos-Silva A, Rumley A, Lowe G, Pereira-Leite L, Quintanilha A, et al. Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. BJOG 2002;109:1250-5.
32. Sekizawa A, Farina A, Sugito Y, Matsuoka R, Iwasaki M, Saito H, et al. Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients. Clin Chem 2004;50:221-4.